Oral contraceptive pill – ethinyl estradiol and drospirenone – 24/4 regimen. Case report Case report
Article Sidebar
Published:
Dec 31, 2015
Keywords:
oral contraceptive pill, ethinyl estradiol, drospirenone
Main Article Content
Abstract
Nowadays, more than 99% of sexually active women in reproductive age have used at least one contraceptive method. The choice of contraceptive method is determined by number of different factors, including age, frequency of sexual activity, number of sexual partners, efficacy, methods acceptance and the woman’s individual risk factors.
Article Details
How to Cite
Błażejewska, A. (2015). Oral contraceptive pill – ethinyl estradiol and drospirenone – 24/4 regimen. Case report. Medycyna Faktow (J EBM), 8(4(29), 61-63. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2284
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Mansour D., Inki P., Gemzell-Danielsson K.: Efficacy of contraceptive methods: A review of the literature. Eur. J. Contracept. Reprod. Health Care 2010; 15: 4-16.
2. Borgelt-Hansen L.: Oral contraceptives: an update on health benefits and risks. J. Am. Pharm. Assoc. (Wash) 2001; 41(6): 875-886.
3. World Health Organization. Contraception in adolescence. WHO Library Cataloguing in Publication Data, Geneva 2004.
4. US Food and Drug Administration (FDA). FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone [online].
5. Food and Drug Administration. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. Silver Spring (MD): FDA; 2011.
6. Burkman R., Schlesselman J.J., Zieman M.: Safety concerns and health benefits associated with oral contraception. Am. J. Obstet. Gynecol. 2004; 190(4 supl.): S5-22.
7. Klipping C., Duijkers I., Trummer D., Marr J.: Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78: 16-25.
8. American College of Obstetricians and Gynecologists. ACOG Committee on Practice Bulletins-Gynecology. Premenstrual syndrome: Clinical management guidelines for obstetrician-gynecologists. ACOG Pract. Bull. 2000; 15: 448-455.
9. Royal College of Obstetricians and Gynaecologists Guideline No. 48. Management of premenstrual syndrome.
10. Clayton A.H.: Symptoms related to the menstrual cycle: diagnosis, prevalence, and treatment. J. Psychiatr. Pract. 2008; 14(1): 13-21.
2. Borgelt-Hansen L.: Oral contraceptives: an update on health benefits and risks. J. Am. Pharm. Assoc. (Wash) 2001; 41(6): 875-886.
3. World Health Organization. Contraception in adolescence. WHO Library Cataloguing in Publication Data, Geneva 2004.
4. US Food and Drug Administration (FDA). FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone [online].
5. Food and Drug Administration. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. Silver Spring (MD): FDA; 2011.
6. Burkman R., Schlesselman J.J., Zieman M.: Safety concerns and health benefits associated with oral contraception. Am. J. Obstet. Gynecol. 2004; 190(4 supl.): S5-22.
7. Klipping C., Duijkers I., Trummer D., Marr J.: Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008; 78: 16-25.
8. American College of Obstetricians and Gynecologists. ACOG Committee on Practice Bulletins-Gynecology. Premenstrual syndrome: Clinical management guidelines for obstetrician-gynecologists. ACOG Pract. Bull. 2000; 15: 448-455.
9. Royal College of Obstetricians and Gynaecologists Guideline No. 48. Management of premenstrual syndrome.
10. Clayton A.H.: Symptoms related to the menstrual cycle: diagnosis, prevalence, and treatment. J. Psychiatr. Pract. 2008; 14(1): 13-21.